Ben Lamm

Who he is

Affiliation: Co-founder & CEO, Colossal Biosciences (2021, Dallas — co-founded with Harvard geneticist George Church). Serial founder before that across software and AI services. Colossal had raised $437M at a $10.2B valuation as of April 2025. Stated targets: woolly mammoth, thylacine, dodo. In April 2025 the company unveiled three canines — Romulus, Remus and Khaleesi — announced as de-extincted dire wolves. At Moonshots LIVE 2026 he does a moonshot interview.
One-line position: Extinction is an engineering problem, and the tools built to reverse it are worth more than the reversals — de-extinction is the flagship that funds and markets a conservation-biotech platform.

Discipline & technical bet

Not a scientist — a serial software founder running a genomics company, with the scientific credibility supplied by George Church and a large staffed research team. That division is the whole structure: Lamm raises, narrates and merchandises; the lab does the biology. The concrete wager is “functional de-extinction” — identify the core genes that produce a species' defining traits and engineer them into the closest living relative, rather than resurrect an exact genome. Commercially the bet is that the tool-chain spins out: the editing, cloning, artificial-womb and biobanking technologies developed to make a mammoth have conservation and biomedical value regardless of whether the mammoth arrives.

Key claims (Says)

• Definitional (and contested): functional de-extinction — a proxy carrying the defining traits counts as the species restored. He cites an IUCN framework in support. This definition is doing enormous work and most of the controversy lives inside it.
• On the dire wolves: the animals possess “nearly all defining characteristics” warranting separate-species classification, backed by a submitted peer-reviewed study arguing dire wolves are a distinct evolutionary lineage.
• On critics: the objection that these are genetically modified grey wolves is “a stupid argument” — his own words, April 2025. Notable for the register, not just the content.
• Normative: de-extinction is conservation, not spectacle — the technology stack transfers directly to saving species that are still alive.
• Commercial: the flagship species exist to “excite children” and carry the biodiversity message. He is unusually candid that the mammoth is a marketing instrument as well as a scientific goal.
• Empirical: the platform generates spinout value independent of the headline projects.

Notable predictions — with falsifiable checks

• Woolly mammoth. Colossal has publicly targeted mammoth calves by 2028. Cleanly falsifiable on a date and the single best test of the entire company. Check: a living calf, gestated and surviving, by 2028-12-31 — and note in advance what will count, because the dire wolf episode shows the definition will be argued after the fact, not before. Decide your own criterion now.
• (April 2025) “We de-extincted the dire wolf.” Contested and, on the strict reading, not established. What was demonstrably done: grey wolf DNA edited for dire-wolf-associated traits (size, white coat), embryos cloned, gestated in a domestic dog surrogate. Critics' position — these are closer to genetically modified designer dogs than to a resurrected species. Both statements are true simultaneously, which is exactly why the framing matters.
• Thylacine and dodo. Announced, no public dated commitment found this pass. Check: does either acquire a published target date, and is that date then met?
• Spinout value. Check: independent revenue or an actual spinout with outside customers by 2028. This is the claim that decides whether Colossal is a biotech platform or a very well-funded exhibition.
• The $10.2B valuation on $437M raised. Check: does the next round hold or exceed that mark, and is it led by a life-sciences investor rather than a generalist or celebrity syndicate? Who prices the round tells you what is being bought.

Revealed behavior (Does)

• Announces first and publishes second. The dire wolves were unveiled to media, with the supporting study submitted around the same time. That ordering is the central behavioral fact — it is a product-launch sequence applied to a scientific claim, and it is why the scientific community reacted the way it did.
• Recruited credibility rather than claiming it. Co-founding with George Church is a genuinely shrewd move and materially different from a founder overselling his own expertise.
• Chose charismatic species deliberately — mammoth, dire wolf, dodo, thylacine. Every one is a story before it is a genome. He says so openly, which is more honest than the alternative.
• Named them Romulus, Remus and Khaleesi. Two founding myths and a Game of Thrones reference. Nobody names research animals that way by accident.
• Fights critics publicly and dismissively rather than engaging the definitional argument, which is the one place he is genuinely vulnerable.

Feels

Evident delight in the audacity of the thing — the sound of a howl, the spectacle, the children. It reads as real rather than manufactured, and it is his most persuasive quality. Underneath, a founder's impatience with gatekeeping that shades into contempt when the gatekeepers are scientists: the “stupid argument” response is the tell. He appears to experience taxonomic objections as pedantry obstructing wonder, which is exactly how a marketer would experience them and not how a scientist would.

Hears

An extraordinarily favourable feed. Enormous popular coverage, celebrity and generalist investors, children writing letters. The scientific criticism reaches him filtered through media framing rather than through peer review, because the announcements precede the papers — by the time specialists respond, the story has already been told. He has constructed an information environment where the applause arrives first and the correction arrives late and quieter.

Sees

Sees extinction as a solvable engineering problem, which is a genuinely generative reframe and the reason serious scientists work there. Also sees, clearly and unsentimentally, that biodiversity loss has a public-attention problem that a mammoth solves and a spreadsheet does not. The blind spot is ecological rather than genetic: producing an organism with a species' traits is not restoring the species' role — habitat, population, behaviour and range are the hard parts, and they are not gene-editing problems.

Incentive map

Very heavy discount, and the structure is unusual. Colossal's valuation rests on narrative more than on revenue — there is no product line, no approvals, no customers of note. Every announcement is a fundraising event. The permissive “functional de-extinction” definition is not incidental: it is the definition under which milestones can be declared, and declared milestones are what support a $10.2B mark on $437M raised.

Cannot say: that the dire wolves are edited grey wolves; that the mammoth timeline may slip; that de-extinction may never be ecologically meaningful; that the conservation framing arrived partly to answer critics. Grade him on the 2028 mammoth date and on whether any spinout ever sells anything — not on unveilings.

Theories aligned with

• Conservation biotech — genetic rescue of living endangered species (the strongest and least contested part of the case)
• Functional de-extinction — proxy species over exact genomes
• Moonshot-as-marketing — a charismatic impossible goal as the engine of funding and attention
• Techno-solutionism, biodiversity variant — extinction as an engineering failure rather than a systems one
• Adjacent to Leapfrog for Good — bypassing slow conservation institutions with capital and technology

What he's reacting against

• Conservation's failure to hold public attention — his most defensible grievance, and largely correct
• Academic caution as an obstacle to ambition
• Grant-cycle science — slow, incremental, structurally unable to attempt something like this
• Taxonomic gatekeeping — he treats species-definition arguments as obstruction rather than as the substance
• Doomer environmentalism — he sells restoration where the field sells loss, which is genuinely differentiated positioning

Where he overlaps / splits (with Rich)

• Overlaps directly with §24 Leapfrog for Good — and is the softer version of the same test Luckey poses. Colossal bypasses the conservation apparatus with capital and technology and delivers a visible outcome. Your leapfrog thesis says do exactly that. He is what leapfrogging looks like when the outcome is real but the claim about it is inflated — a failure mode your framing hasn't yet named.
• Splits hard on §11 research standards, and this is the important one. Announce-then-publish is the inverse of “research like a scientist.” Your whole persona apparatus grades people on falsifiability and calibrated language; Colossal's central claim rests on a definition chosen by the claimant. If you keep one line from this file, keep that.
• Overlaps on the XPRIZE Lens — would someone fund this because it matters? Colossal is the purest existing example of impact-framing successfully attracting non-impact capital.
• Splits on §14 embrace the tensions. The genuine tension here — spectacle funds the science and spectacle corrupts the claims — is one he refuses to hold. He resolves it by calling the critics stupid. You would hold it; that difference is the whole read on him.
• Connects to Caring. Biodiversity sits in your Caring domain alongside public lands. The useful question is whether de-extinction moves conservation outcomes or diverts attention and money from habitat — and that question is genuinely open, not rhetorical.
• Overlaps with Diamandis on moonshot-as-attention-machine; both understand that an impossible goal is a funding instrument.
• Splits with Mollick and Mitchell in temperament — they are the empiricist counterweight your bench uses, and they would not let the dire wolf framing pass.

Track record

Verified: Colossal founded 2021 with George Church; $437M raised at a $10.2B valuation (April 2025); three edited canines produced, gestated and born, April 2025; a peer-reviewed study on dire wolf lineage submitted. Prior to Colossal, multiple software and AI-services companies founded and exited.

The honest read: as a founder, the record is real — he raised a very large round for a genuinely hard scientific programme and assembled serious people to run it. As a de-extinction record, nothing has yet been established on the strict reading of the claim. Those are different scoreboards and his coverage consistently merges them. The 2028 mammoth date is when they separate.

Empirical vs normative

Empirical (verifiable): the edits made, the animals produced, the surrogate species, the funding and valuation. Definitional (presented as empirical — the crux): that the result is a dire wolf. This is not a finding, it is a category judgment made by the party who benefits from it, delivered in the grammar of a result. Normative: that de-extinction is a worthwhile use of capital and attention.

The pattern to name: the strongest claim in the corpus is a definition, and it is announced as though it were data. That is the same rhetorical move Salim Ismail makes with the Organizational Singularity, in a different field.

Weak spots / open questions

• The definition is the product. “Functional de-extinction” is chosen by the claimant and makes the claim true by construction.
• Announce-then-publish. Reverses the epistemic order and ensures the correction never catches the claim.
• Ecology, not genetics, is the hard part. An organism with mammoth traits is not a restored mammoth ecology — habitat, population viability, range and learned behaviour are unaddressed.
• Valuation rests on announcements, not revenue, approvals or customers.
• The conservation framing may be retrofitted. Open question: was the spinout-and-conservation case central at founding, or did it strengthen as criticism arrived? Checkable against 2021–22 materials.
• Question worth asking him directly: what result, on the mammoth, would he accept as a failure — and who decides?

Rich's take

• (your synthesis here)

Delta log

2026-09-05 — created

• New persona at v2 depth for Moonshots LIVE 2026-09-25 (moonshot interview).
• Verified this pass: the dire wolf method (grey wolf edits, cloning, domestic dog surrogate), the three animals and their names, the “functional de-extinction” definition and IUCN framing, the “stupid argument” quote, the submitted lineage study, $437M raised at $10.2B (Fast Company, 2025-04-12); the flagship-species-as-message framing (Nature careers feature, 2025-09-25 — headline and framing only, full text paywalled).
• Not verified this pass: the 2028 mammoth target is carried from general knowledge and should be confirmed against a Colossal primary source before being used as a scoring date. The George Church co-founding is well established but was not separately sourced here.
• Framed the finding that earns the file: the strongest claim in the corpus is a definition delivered in the grammar of a result — the same move logged against Salim Ismail on the same day, in a different field. Worth watching for as a pattern across this bill.
• Named the failure mode his case adds to §24: leapfrogging where the outcome is real and the claim about it is inflated.
• Confidence medium — the financials and method are documented; the timelines and the spinout case are not.

Sources

• Fast Company, 2025-04-12 — Lamm defends the ‘de-extinct’ dire wolves (method, criticism, quotes, valuation)
• Nature, 2025-09-25 — “Mammoth challenge: why we called our de-extinction company Colossal” (framing; full text paywalled)
• Moonshots LIVE 2026 — session
• Not consulted: Colossal's own site and published papers, the dire wolf preprint, IUCN's actual de-extinction guidelines. Next pass — the IUCN document in particular, since his defence rests on it.